Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425876 | 0.78 | DHFR (0.52) | DHFRALDH1A1CYP2D6ATM | |
| SCHEMBL14520696 | 0.75 | SLC2A1 (0.45) | DHFRSLC2A1TLR8APP | |
| SCHEMBL5434583 | 0.71 | DHFR (0.47) | DHFRSLC2A1CYP2D6 | |
| SCHEMBL10645923 | 0.65 | DHFR (0.55) | DHFR | |
| SCHEMBL11012896 | 0.65 | DHFR (0.49) | DHFRALDH1A1 | |
| SCHEMBL28201802 | 0.65 | CYP2D6 (0.59) | ALDH1A1CYP2D6ATM | |
| SCHEMBL4943905 | 0.64 | DHFR (0.78) | DHFR | |
| SCHEMBL10649711 | 0.64 | DHFR (0.55) | DHFR | |
| SCHEMBL4942378 | 0.63 | DHFR (0.48) | DHFR | |
| SCHEMBL3698261 | 0.63 | TLR7 (0.74) | DHFRTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | LIG3, LIG1, NQO1 | DHFR 171/4885SLC2A1 4692/4885ALDH1A1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.